Latest Recruitment News

Lumos Diagnostics has enrolled 500 patients in its FebriDx CLIA waiver clinical study, unlocking a significant milestone payment from BARDA and moving closer to FDA approval that could open a US$1 billion market.

Avenira Limited has secured Northern Territory Government approval for its Wonarah Direct Shipping Ore Mine Management Plan, paving the way for first ore shipment by Q4 2025. The project includes infrastructure development and exploration drilling to support future beneficiation.

Linius Technologies secures $3.3 million through share placement and convertible notes, appointing former AFL CEO Andrew Demetriou to its board as it accelerates commercial momentum under new leadership.

Astron Corporation is set to redomicile from Hong Kong to Australia, establishing a new Australian parent company and simplifying shareholder engagement. This move aims to align governance with local standards and boost investor confidence.

HeraMED has partnered with RMIT University and the Digital Health CRC to develop AI-driven maternity care models focused on culturally diverse populations, aiming to improve pre-term delivery risk prediction and personalised care.

EDU Holdings reports a remarkable 118% increase in total student enrolments at its Ikon Institute for Trimester 2, 2025, driven by strong demand and new course offerings amid a shifting regulatory landscape.

Dimerix has reached a key milestone by dosing 200 adult patients in its Phase 3 ACTION3 trial for FSGS, progressing steadily toward full recruitment expected in late 2025.

Syntara Limited is set to reveal fresh interim results from its Phase 2 trial of SNT-5505, targeting myelofibrosis, during an investor webinar ahead of a major European hematology conference.

Bowen Coking Coal is set to transition its Burton Mine Complex to an owner-operator model from July 1, 2025, aiming to increase production and reduce costs. This strategic shift marks a new chapter in Bowen’s operational control and growth ambitions.

Paradigm Biopharmaceuticals has reached key milestones in its global Phase 3 trial for knee osteoarthritis, activating its first Australian clinical site and enrolling the first patient. With multiple sites in Australia and the US preparing for recruitment, the trial is advancing steadily toward critical data readouts.

Lumos Diagnostics has reached 50% recruitment of bacterial positive patients in its pivotal FebriDx CLIA waiver clinical study, setting the stage for a planned FDA submission in late 2025 and unlocking a substantial US market opportunity.

Amplia Therapeutics reports strong progress in its pancreatic cancer drug development, completing the ACCENT trial recruitment ahead of schedule and initiating a new US trial, while managing a $6.57 million loss for FY25.